Related Experiment Video
Updated: Jul 17, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases-by DahShu Innovative Design Scientific
Chenkun Wang1, Junrui Di2, Mercedeh Ghadessi3
1Vertex Pharmaceuticals, Inc., 50 Northern Avenue, Boston, MA, 02210, USA. Chenkun_Wang@vrtx.com.
Abstract:
The rapid advancement of cell and gene therapies (CGT) in the past ten years has inspired biopharmaceutical companies, biotechnologies, and nonprofits to tackle diseases that have traditionally been challenging to treat. Rare diseases, where roughly 80% have a genetic basis, have enjoyed this scrutiny, but the complexity of CGT trial design and implementation have proven challenging. This manuscript offers general guidance for CGT clinical development, current regulatory requirements and guidelines governed by FDA and EMA, considerations around preclinical development, safety monitoring and the need for long-term monitoring and follow up.
Related Concept Videos
Gene Therapy
iPS Cell Differentiation
EPS and iPS Cells in Disease Research
Preclinical Development: Overview

